Clinical Research Directory
Browse clinical research sites, groups, and studies.
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Sponsor: Roswell Park Cancer Institute
Summary
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
Official title: A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-01-02
Completion Date
2026-07-02
Last Updated
2025-04-25
Healthy Volunteers
No
Conditions
Interventions
Blood sample
To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
Locations (2)
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Good Samaritan University Hospital
West Islip, New York, United States